Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Status unknown · Phase 1 · NCT03703063
Conditions: Pancreatic Adenocarcinoma
At a glance
- Research payments reported, 2025
- $216,365
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- Benaroya Research Institute
- Tested
- Gemcitabine (drug), nab paclitaxel (drug), Onivyde (drug), Leucovorin (drug), 5-fu (drug)
- Dates
- Started 2018-09-17; completion 2022-09-17
- Results posted
- Not yet
Using alternative neoadjuvant gemcitabine-nab-paclitaxel and nal-IRI with 5-Fluorouracil (5FU) and folinic acid (Leucovorin) regimens of localized cancer, we hope to ensure exposure of the cancer to a broader array of potentially active agents. Also, potentially improves patient tolerance and minimizes significant drug toxicity that could impair delivery of all treatment elements. Furthermore, it may enable prediction of superior to inferior treatment outcomes at an earlier point in the disease progress.
From ClinicalTrials.gov, last updated 2021-01-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $216,365 in research payments for this study in 2025 (2 payments).
Products named: Onivyde
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Virginia Mason Clinic $216,365
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.